Prevention and control of hepatitis A
- 1 February 1994
- journal article
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 32 (2) , 9-11
- https://doi.org/10.1136/dtb.1994.3229
Abstract
Until recently, protection against hepatitis A has depended on high standards of public health and hygiene, bolstered by selective passive immunisation of those at high risk of infection using human normal immunoglobulin (HNIG). The scope for prophylaxis changed in April 1992 with the introduction of a hepatitis A vaccine (▼Havrix - SmithKline Beecham), which offers active immunisation and so longer and more effective protection than HNIG. In this article we discuss the epidemiology of hepatitis A and the methods of prevention and control of the infection. We also appraise the vaccine and consider how it should be used.Keywords
This publication has 12 references indexed in Scilit:
- Safety and immunogenicity of hepatitis A vaccine in healthy childrenThe Pediatric Infectious Disease Journal, 1993
- A Controlled Trial of a Formalin-Inactivated Hepatitis A Vaccine in Healthy ChildrenNew England Journal of Medicine, 1992
- Clinical trial with inactivated hepatitis A vaccine and recommendations for its use.BMJ, 1992
- Immunoglobulin Prophylaxis for Hepatitis AClinical Infectious Diseases, 1992
- Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findingsVaccine, 1992
- Persistence of vaccine-induced antibody to hepatitis A virusVaccine, 1992
- Hepatitis A outbreak involving bread.Epidemiology and Infection, 1991
- Viral HepatitisPublished by Springer Nature ,1991
- Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteersVaccine, 1990
- Reports of clinical hepatitis A from Public Health and hospital microbiology laboratories to the PHLS Communicable Disease Surveillance Centre during the period 1980–1988Journal of Infection, 1990